Cancer Treatment
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Unlock global cancer treatment market insights. Stay ahead on drug approvals, clinical trials, and therapeutic advancements for pharma investors & BD.
Showing 1–11 of 11 articles
Quick answer
NovaPharmaNews Cancer Treatment hub for EMA covers 11 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Pfizer's Talzenna Combo: A Game Changer in Prostate Cancer Treatment
NICE Technology Appraisals: Impact on Market Access for Novel Oncology Drugs
HTA Outcomes Oncology Therapies: G-BA vs NICE Post-Brexit Analysis
ASCO 2026: Olverembatinib Data & Gastric Cancer Trial Updates
CAR-T Therapies Cost-Effectiveness: EU HTA Bodies' Divergent Assessments
EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026
TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies
TME Pharma NOX-A12 Triple Therapy Shows Promise in Brain Cancer GLORIA Trial Published in Nature Communications
EMA Conditional Approval CAR-T Therapy for Relapsed B-Cell Lymphoma
EMA Issues Positive Opinion for Zepzelca (Lurbinectedin) in Cancer Treatment
EMA Issues Positive Opinion for Adstiladrin Gene Therapy in Bladder Cancer Treatment
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.